Auditory mismatch negativity deficits in long-term heavy cannabis users

  • Patrik Roser
  • Beate Della
  • Christine Norra
  • Idun Uhl
  • Martin Brüne
  • Georg Juckel
Original Paper

Abstract

Mismatch negativity (MMN) is an auditory event-related potential indicating auditory sensory memory and information processing. The present study tested the hypothesis that chronic cannabis use is associated with deficient MMN generation. MMN was investigated in age- and gender-matched chronic cannabis users (n = 30) and nonuser controls (n = 30). The cannabis users were divided into two groups according to duration and quantity of cannabis consumption. The MMNs resulting from a pseudorandomized sequence of 2 × 900 auditory stimuli were recorded by 32-channel EEG. The standard stimuli were 1,000 Hz, 80 dB SPL and 90 ms duration. The deviant stimuli differed in duration (50 ms) or frequency (1,200 Hz). There were no significant differences in MMN values between cannabis users and nonuser controls in both deviance conditions. With regard to subgroups, reduced amplitudes of frequency MMN at frontal electrodes were found in long-term (≥8 years of use) and heavy (≥15 joints/week) users compared to short-term and light users. The results indicate that chronic cannabis use may cause a specific impairment of auditory information processing. In particular, duration and quantity of cannabis use could be identified as important factors of deficient MMN generation.

Keywords

Cannabis Long-term effects Cognitive deficits Event-related potentials Mismatch negativity 

References

  1. 1.
    Association American Psychiatric (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  2. 2.
    Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002) Dose-related neurocognitive effects of marijuana use. Neurology 59:1337–1343PubMedGoogle Scholar
  3. 3.
    Brown J, Kranzler HR, Del Boca FK (1992) Self-reports by alcohol and drug abuse inpatients: factors affecting reliability and validity. Br J Addict 87:1013–1024CrossRefPubMedGoogle Scholar
  4. 4.
    D’Souza DC (2007) Cannabinoids and psychosis. Int Rev Neurobiol 78:289–326CrossRefPubMedGoogle Scholar
  5. 5.
    D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608CrossRefPubMedGoogle Scholar
  6. 6.
    D’Souza DC, Sewell RA, Ranganathan M (2009) Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 259:413–431CrossRefPubMedGoogle Scholar
  7. 7.
    ElSohly MA, Slade D (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78:539–548CrossRefPubMedGoogle Scholar
  8. 8.
    Emrich HM, Leweke FM, Schneider U (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56:803–807CrossRefPubMedGoogle Scholar
  9. 9.
    Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647CrossRefGoogle Scholar
  10. 10.
    Hall W, Degenhardt L (2000) Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust N Z J Psychiatry 34:26–34CrossRefPubMedGoogle Scholar
  11. 11.
    Harrison ER, Haaga J, Richards T (1993) Self reported drug use data: what do they reveal? Am J Drug Alcohol Abuse 19:423–441CrossRefPubMedGoogle Scholar
  12. 12.
    Heekeren K, Daumann J, Neukirch A, Stock C, Kawohl W, Norra C, Waberski TD, Gouzoulis-Mayfrank E (2008) Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology 199:77–88CrossRefPubMedGoogle Scholar
  13. 13.
    Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932–1936CrossRefPubMedGoogle Scholar
  14. 14.
    Javitt DC, Doneshka P, Grochowski S, Ritter W (1995) Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry 52:550–558PubMedGoogle Scholar
  15. 15.
    Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC (1996) Role of cortical N-methyl-d-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci USA 93:11962–11967CrossRefPubMedGoogle Scholar
  16. 16.
    Juckel G, Roser P, Nadulski T, Gallinat J, Stadelmann AM (2007) Acute effects of delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 97:109–117CrossRefPubMedGoogle Scholar
  17. 17.
    Kempel P, Lampe K, Parnefjord R, Hennig J, Kunert HJ (2003) Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls. Neuropsychobiology 48:95–101CrossRefPubMedGoogle Scholar
  18. 18.
    Lepistö T, Silokallio S, Nieminen-von Wendt T, Alku P, Näätänen R, Kujala T (2006) Auditory perception and attention as reflected by the brain event-related potentials in children with Asperger syndrome. Clin Neurophysiol 117:2161–2171CrossRefPubMedGoogle Scholar
  19. 19.
    Lundqvist T (2005) Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 81:319–330CrossRefPubMedGoogle Scholar
  20. 20.
    Lundqvist T, Jönsson S, Warkentin S (2001) Frontal lobe dysfunction in long-term cannabis users. Neurotoxicol Teratol 23:437–443CrossRefPubMedGoogle Scholar
  21. 21.
    McPartland JM (2008) Adulteration of cannabis with tobacco, calamus, and other cholinergic compounds. Cannabinoids 3:16–20Google Scholar
  22. 22.
    Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42(Suppl 11):11S–19SPubMedGoogle Scholar
  23. 23.
    Näätänen R (1995) The mismatch negativity: a powerful tool for cognitive neuroscience. Ear Hear 16:6–18CrossRefPubMedGoogle Scholar
  24. 24.
    Näätänen R, Alho K (1995) Generators of electrical and magnetic mismatch responses in humans. Brain Topogr 7:315–320CrossRefPubMedGoogle Scholar
  25. 25.
    Näätänen R, Michie PT (1979) Early selective-attention effects on the evoked potential: a critical review and reinterpretation. Biol Psychol 8:81–136CrossRefPubMedGoogle Scholar
  26. 26.
    Näätänen R, Paavilainen P, Tiitinen H, Jiang D, Alho K (1993) Attention and mismatch negativity. Psychophysiology 30:436–450CrossRefPubMedGoogle Scholar
  27. 27.
    Noland JS, Singer LT, Short EJ, Minnes S, Arendt RE, Kirchner HL, Bearer C (2005) Prenatal drug exposure and selective attention in preschoolers. Neurotoxicol Teratol 27:429–438CrossRefPubMedGoogle Scholar
  28. 28.
    Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97–113CrossRefPubMedGoogle Scholar
  29. 29.
    Quickfall J, Crockford D (2006) Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci 18:318–332PubMedGoogle Scholar
  30. 30.
    Pekkonen E (2000) Mismatch negativity in aging and in Alzheimer’s and Parkinson’s diseases. Audiol Neurootol 5:216–224CrossRefPubMedGoogle Scholar
  31. 31.
    Potvin S, Joyal CC, Pelletier J, Stip E (2008) Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res 100:242–251CrossRefPubMedGoogle Scholar
  32. 32.
    Ritter W, Deacon D, Gomes H, Javitt DC, Vaughan HG Jr (1995) The mismatch negativity of event-related potentials as a probe of transient auditory memory: a review. Ear Hear 16:52–67CrossRefPubMedGoogle Scholar
  33. 33.
    Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2–14PubMedGoogle Scholar
  34. 34.
    Roser P, Vollenweider FX, Kawohl W (2008) Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry. 7:1–12. doi:10.1080/15622970801908047 Google Scholar
  35. 35.
    Roser P, Stadelmann AM, Arning L, Gallinat J, Epplen JT, Juckel G (2008) Acute effects of Δ9-tetrahydrocannabinol on the auditory event-related mismatch negativity depending on genetic variations in the dysbindin, neuregulin and G72 gene. Int J Neuropsychopharmacol 11(Suppl 1):256Google Scholar
  36. 36.
    Sarne Y, Mechoulam R (2005) Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 4:677–684CrossRefPubMedGoogle Scholar
  37. 37.
    Scallet AC (1991) Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 40:671–676CrossRefPubMedGoogle Scholar
  38. 38.
    Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33Google Scholar
  39. 39.
    Shelley AM, Ward PB, Catts SV, Michie PT, Andrews S, McConaghy N (1991) Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 30:1059–1062CrossRefPubMedGoogle Scholar
  40. 40.
    Solowij N (1998) Cannabis and cognitive functioning. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  41. 41.
    Solowij N, Michie PT, Fox AM (1991) Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol Biochem Behav 40:683–688CrossRefPubMedGoogle Scholar
  42. 42.
    Solowij N, Michie PT, Fox AM (1995) Differential impairment of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 37:731–739CrossRefPubMedGoogle Scholar
  43. 43.
    Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287:1123–1131CrossRefPubMedGoogle Scholar
  44. 44.
    Sussman E, Ritter W, Vaughan HG Jr (1998) Attention affects the organization of auditory input associated with the mismatch negativity system. Brain Res 789:130–138CrossRefPubMedGoogle Scholar
  45. 45.
    Umbricht D, Krljes S (2005) Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76:1–23CrossRefPubMedGoogle Scholar
  46. 46.
    Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57:1139–1147CrossRefPubMedGoogle Scholar
  47. 47.
    Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80:1415–1419CrossRefPubMedGoogle Scholar
  48. 48.
    Wobrock T, Sittinger H, Behrendt B, D’Amelio R, Falkai P, Caspari D (2007) Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 257:203–210CrossRefPubMedGoogle Scholar
  49. 49.
    Wobrock T, Sittinger H, Behrendt B, D’Amelio R, Falkai P (2009) Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci 259:28–36CrossRefPubMedGoogle Scholar
  50. 50.
    Woldorff MG, Hillyard SA, Gallen CC, Hampson SR, Bloom FE (1998) Magnetoencephalographic recordings demonstrate attentional modulation of mismatch-related neural activity in human auditory cortex. Psychophysiology 35:283–292CrossRefPubMedGoogle Scholar
  51. 51.
    Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, Lubman DI (2008) Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 65:694–701CrossRefPubMedGoogle Scholar
  52. 52.
    Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimarães FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39:421–429CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Patrik Roser
    • 1
  • Beate Della
    • 1
  • Christine Norra
    • 1
  • Idun Uhl
    • 1
  • Martin Brüne
    • 1
  • Georg Juckel
    • 1
  1. 1.Department of PsychiatryRuhr-University BochumBochumGermany

Personalised recommendations